Lung Cancer Screening & Diagnosis

📋 Key Information Summary

📋

Lung cancer is the leading cause of cancer death in Australia, with approximately 13,000 new diagnoses annually; five-year survival remains below 20% due to late-stage presentation.
Low-dose CT (LDCT) screening reduces lung cancer mortality by 20% in high-risk populations; recommended annually for adults aged 50–80 years with ≥20 pack-year smoking history and current smoking or cessation within 15 years (USPSTF 2021 criteria).
Australia has not yet implemented a national lung cancer screening programme, though the Department of Health has announced LungCheck — a planned national programme expected to commence in 2025.
Pulmonary nodule evaluation follows Fleischner Society 2017 guidelines for incidental nodules and Lung-RADS for screening-detected nodules; solid nodules <6 mm in low-risk patients typically require no further follow-up.
PET-CT is indicated for solid nodules ≥8 mm with intermediate-to-high pre-test probability of malignancy; it has limited utility for ground-glass nodules and nodules <8 mm.
Tissue diagnosis via bronchoscopy (EBUS, navigational bronchoscopy) or CT-guided transthoracic needle biopsy is required before treatment; the approach depends on lesion location, size, and accessibility.
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is the first-line modality for mediastinal lymph node staging, with sensitivity of 89–93% and specificity approaching 100%.
Molecular testing (EGFR, ALK, ROS1, BRAF, KRAS G12C, PD-L1, NTRK, MET, RET) is mandatory for all newly diagnosed non-small cell lung cancer (NSCLC) specimens, regardless of histological subtype.
TNM 8th edition staging guides treatment planning; staging is clinical (cTNM) at diagnosis and pathological (pTNM) after surgical resection.
Multidisciplinary team (MDT) discussion is mandatory for every new lung cancer diagnosis in Australia, as per Optimal Care Pathway for Lung Cancer (Cancer Council Victoria / ACSQHC).
Aboriginal and Torres Strait Islander Australians have 1.8× higher lung cancer incidence and significantly lower five-year survival than non-Indigenous Australians; culturally safe screening access and smoking cessation programmes are critical.
Performance status (ECOG/Karnofsky) is a key determinant of treatment eligibility; ECOG 0–2 generally qualifies for curative-intent therapy.

Introduction & Australian Epidemiology

Lung cancer remains the most lethal malignancy in Australia and worldwide, responsible for more deaths than colorectal, breast, and prostate cancers combined. In 2024, an estimated 13,800 new cases were diagnosed in Australia, with a five-year survival rate of approximately 18–22% — a figure that has improved only modestly over the past two decades, largely because most patients present with advanced-stage disease.

The majority (approximately 85%) of lung cancers are non-small cell lung cancer (NSCLC), comprising adenocarcinoma (~40%), squamous cell carcinoma (~25%), and large cell carcinoma (~10–15%). Small cell lung cancer (SCLC) accounts for approximately 13–15% and is strongly associated with smoking. Rarer subtypes include large cell neuroendocrine carcinoma and pulmonary carcinoid tumours.

Australian Burden of Disease

Incidence: Lung cancer is the fifth most commonly diagnosed cancer in Australia (age-standardised rate ~35 per 100,000).
Mortality: Approximately 9,400 deaths per year; the age-standardised mortality rate is ~25 per 100,000.
Trends: Incidence in males has declined since the 1980s reflecting reduced smoking rates; female incidence has plateaued and may increase due to later adoption of smoking by women.
Aboriginal and Torres Strait Islander peoples: Age-standardised incidence is 1.8 times higher, with mortality rates 1.9 times higher than non-Indigenous Australians (AIHW 2023).
Socioeconomic disparity: Lung cancer incidence is approximately 2.5 times higher in the most disadvantaged quintile compared to the most advantaged.
Geographic variation: Rural and remote populations experience later-stage diagnosis and reduced access to specialist services, particularly PET-CT and bronchoscopy.

Risk Factors

Risk Factor	Relative Risk	Australian Relevance
Active smoking	15–30×	11% of Australian adults smoke daily (2022–23 NDSHS)
Former smoking (quit <15 years)	5–10×	Large eligible screening population
Second-hand smoke	1.2–1.3×	Relevant in household and workplace settings
Occupational carcinogens (asbestos, silica, diesel exhaust)	2–5×	Mining and construction industries; legacy asbestos in older buildings
Radon exposure	1.5–3×	Lower prevalence than Northern Hemisphere; relevant in some geological regions
Family history (first-degree relative)	1.5–2×	Independent of smoking status
COPD / pulmonary fibrosis	2–5×	High prevalence in smoking population and Aboriginal communities
Prior chest radiotherapy	2–10×	E.g., for Hodgkin lymphoma or breast cancer

⚠️

Never-smokers account for 10–15% of lung cancers in Australia. In never-smokers, adenocarcinoma is the predominant histology, and actionable driver mutations (EGFR, ALK, ROS1) are more frequent (up to 50–60% harbour targetable alterations). Clinical suspicion should not be reduced solely because the patient is a non-smoker.

Screening Guidelines

Lung cancer screening with low-dose computed tomography (LDCT) is the only evidence-based modality shown to reduce lung cancer mortality. Two landmark randomised controlled trials — the National Lung Screening Trial (NLST, 2011) and the NELSON trial (2020) — demonstrated 20% and 24% relative reductions in lung cancer mortality, respectively, in high-risk populations screened with LDCT compared to chest radiography or no screening.

USPSTF 2021 Screening Recommendations

The United States Preventive Services Task Force (USPSTF) provides the most widely adopted eligibility criteria:

✅

USPSTF Grade B Recommendation (2021): Annual LDCT screening for adults who meet ALL of the following criteria:

Age 50 to 80 years
≥20 pack-year smoking history (1 pack/day × 20 years, or equivalent)
Currently smoking OR quit within the past 15 years

Screening should be discontinued once a person has not smoked for >15 years or develops a health condition that substantially limits life expectancy or the ability/willingness for curative-intent treatment.

Criterion	USPSTF 2021	NELSON Trial Criteria	Proposed Australian (LungCheck)
Age	50–80 years	50–75 years	50–80 years
Smoking history	≥20 pack-years	>15 cigs/day for >25 yrs OR >10 cigs/day for >30 yrs	≥20 pack-years (anticipated)
Smoking status	Current or quit ≤15 years	Current or quit ≤10 years	Current or quit ≤15 years (anticipated)
Screening interval	Annual	Baseline, 1 yr, 3 yrs, 5.5 yrs	Annual (anticipated)
Mortality reduction	20% (NLST)	24% (NELSON)	Expected comparable

Australian Screening Context

⚠️

No national lung cancer screening programme exists in Australia as of early 2025. The Australian Government announced the National Lung Cancer Screening Programme (LungCheck), with an expected commencement date of mid-2025. In the interim, LDCT screening is not routinely funded under Medicare; it may be performed at specialist request but is not rebated as a screening test. Clinicians should assess eligibility using USPSTF 2021 criteria and refer eligible patients to multidisciplinary thoracic centres for discussion.

Low-Dose CT Protocol

Technique: Non-contrast, volumetric acquisition through the entire chest; slice thickness ≤1.25 mm (ideally ≤1 mm); low radiation dose ≤2 mGy (CTDIvol); no IV contrast required.
Reporting: Should use Lung-RADS (Lung CT Screening Reporting and Data System) classification.
Nodule volumetry: Automated volumetric measurement with volumetric doubling time (VDT) calculation is preferred over manual diameter measurement (NELSON protocol).
Incidental findings: Coronary artery calcification, emphysema, osteoporosis, thyroid nodules, adrenal lesions, and hepatic lesions are frequently identified and must be reported.

Lung-RADS Classification for Screening Nodules

Lung-RADS	Category	Findings	Management
1	Negative	No pulmonary nodules; clearly benign nodules	Continue annual LDCT
2	Benign	Solid nodule <6 mm; new solid <4 mm; part-solid <6 mm total; GGN <30 mm stable	Continue annual LDCT
3	Probably Benign	Solid 6–<8 mm; new solid 4–<6 mm; part-solid ≥6 mm with solid <6 mm; new GGN ≥30 mm	6-month LDCT follow-up
4A	Suspicious	Solid 8–<15 mm; new/growing 6–<8 mm; part-solid with solid component 6–<8 mm	3-month LDCT; PET-CT; tissue sampling
4B	Very Suspicious	Solid ≥15 mm; new/growing ≥8 mm; part-solid with solid ≥8 mm	PET-CT; tissue sampling; consider surgical biopsy
4X	Suspicious + Extra-thoracic	Category 3/4 with additional suspicious features (e.g., lymphadenopathy, pleural effusion)	Urgent tissue sampling; specialist referral
S	Other	Clinically significant non-pulmonary findings	Appropriate workup per finding

Harms and Limitations of Screening

False-positive rate: Approximately 23–27% of screening rounds in the NLST yielded a false-positive result; the positive predictive value of a positive screen is approximately 3–4%.
Overdiagnosis: Estimated at 10–20% of screen-detected cancers, particularly slow-growing adenocarcinomas and ground-glass nodules.
Radiation exposure: Cumulative dose over multiple rounds is low (~1.5 mSv per scan) but must be considered in the context of repeated screening.
Psychological impact: False-positive results cause significant anxiety; shared decision-making is essential before initiating screening.
Invasive procedures: Approximately 1–3% of screened individuals undergo an invasive procedure for a benign nodule.

Shared Decision-Making

Current guidelines (USPSTF, NCCN, ACS) recommend a shared decision-making conversation before ordering screening LDCT. This discussion should cover:

The individual's lung cancer risk (pack-years, age, comorbidities)
Benefits of screening (20–24% mortality reduction)
Potential harms (false positives, invasive procedures, overdiagnosis)
Importance of continued smoking cessation
Willingness to undergo further investigation and potential treatment

Pulmonary Nodule Evaluation

Pulmonary nodules are increasingly detected as incidental findings on CT imaging performed for other indications (cardiac CT, CT pulmonary angiography, low-dose CT for calcium scoring, COVID-19 pneumonia follow-up). Incidental pulmonary nodules are identified in approximately 20–30% of chest CT scans. The Fleischner Society guidelines provide evidence-based recommendations for managing incidental pulmonary nodules based on size, morphology, and patient risk factors.

Nodule Morphology and Terminology

Type	Definition	Differential Diagnosis	Malignancy Risk
Solid nodule	Homogeneous soft tissue attenuation that completely obscures parenchyma	Granuloma, hamartoma, intrapulmonary lymph node, lung cancer, metastasis	Varies by size and risk factors
Ground-glass nodule (GGN)	Hazy increased attenuation without obscuring bronchial/vascular markings	Atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS), inflammation	Generally lower but may represent early adenocarcinoma
Part-solid (mixed) nodule	Both ground-glass and solid components	Minimally invasive adenocarcinoma (MIA), invasive adenocarcinoma	Highest malignancy risk (63–80% if ≥8 mm solid component)
Subsolid nodule	Umbrella term for GGN + part-solid	See above	Intermediate
Cavitary nodule	Nodule with central lucency; wall thickness ≥4 mm suggests malignancy	Squamous cell carcinoma, infection (TB, fungal), granulomatosis with polyangiitis	Increased with thick irregular walls
Calcified nodule	Central, laminated, popcorn, or diffuse calcification pattern	Granuloma, hamartoma (popcorn calcification)	Very low (typically benign)

Fleischner Society 2017 Guidelines — Incidental Solid Nodules

ℹ️

The Fleischner Society guidelines apply to incidentally detected pulmonary nodules in patients aged ≥35 years. They do NOT apply to immunocompromised patients or those with known extrapulmonary malignancy (which require individualised management). For screening-detected nodules, use Lung-RADS (see above).

Low-Risk Patients

(Minimal or absent smoking history; no other risk factors)

Nodule Size	Recommendation	Follow-up
<6 mm	No routine follow-up	None required
6–8 mm	CT at 6–12 months, then consider CT at 18–24 months	6–12 months, then 18–24 months
>8 mm	CT at 3 months; PET-CT; or tissue sampling	3 months (CT), or consider PET-CT/biopsy at presentation

High-Risk Patients

(Smoking, family history, upper-lobe emphysema, occupational exposures)

Nodule Size	Recommendation	Follow-up
<6 mm	Optional CT at 12 months	12 months (optional)
6–8 mm	CT at 6–12 months, then CT at 18–24 months	6–12 months, then 18–24 months
>8 mm	CT at 3 months; PET-CT; or tissue sampling	3 months (CT), or consider PET-CT/biopsy at presentation

Fleischner Society 2017 — Incidental Subsolid Nodules

Nodule Type	Size	Recommendation	Follow-up
Solitary GGN	<6 mm	No routine follow-up	None required
Solitary GGN	≥6 mm	CT at 6–12 months, then every 2 years for 5 years	6–12 mo, then 2-yearly × 5 yrs
Solitary part-solid	≥6 mm	CT at 3–6 months; if solid component ≥6 mm and persists → PET-CT or biopsy	3–6 months; further based on evolution
Multiple subsolid	Variable	CT at 3–6 months; if stable/dominant lesion ≥6 mm → CT at 2 and 4 years	3–6 months, then 2 and 4 years

PET-CT Indications

FDG PET-CT (MBS item 61338 — requires Medicare-eligible indication) plays a critical role in nodule evaluation and staging but has specific strengths and limitations:

📡

FDG PET-CT

18F-fluorodeoxyglucose positron emission tomography–CT

Best indication Solid nodule ≥8 mm with intermediate pre-test probability of malignancy (5–65%); staging of NSCLC

Sensitivity (nodule) ~97% for solid nodules >8 mm; poor for GGN and carcinoid

Specificity (nodule) ~85%; false positives in infection/inflammation (TB, fungal, sarcoidosis)

Limitations Low sensitivity for nodules <8 mm; GGN; mucinous adenocarcinoma; carcinoid; brain (high background)

SUVmax threshold >2.5 suggestive of malignancy (but overlap with inflammatory conditions)

PBS/MBS status ⚠ MBS 61338 — Authority required for specific indications

⚠️

PET-CT does NOT replace tissue biopsy. A positive PET-CT provides supporting evidence but is insufficient for treatment planning. Histological or cytological confirmation of malignancy is required before initiating cancer therapy. Conversely, a negative PET-CT in a suspicious lesion does not exclude malignancy, particularly for low-grade tumours (carcinoid, well-differentiated adenocarcinoma) and subsolid nodules.

Biopsy Techniques for Nodule Sampling

1

CT-Guided Transthoracic Needle Biopsy (TTNB)

Peripheral nodules; sensitivity 90–95%; pneumothorax risk 15–25% (chest drain needed in 5–10%); MBS item 55064.

2

Bronchoscopy with Biopsy

Central lesions; conventional bronchoscopy for endobronchial disease; sensitivity 60–75% for central tumours.

3

Navigation Bronchoscopy

Peripheral nodules difficult to reach with standard bronchoscopy; diagnostic yield 70–85%; lower pneumothorax risk (~3%).

4

Surgical Biopsy (VATS / Thoracotomy)

When less invasive methods are non-diagnostic or when wedge resection achieves both diagnosis and treatment; sensitivity near 100%.

Nodule Growth Assessment

Solid nodule growth: An increase in mean diameter of ≥2 mm on CT is considered significant growth.
Volumetric doubling time (VDT): Malignant solid nodules typically have VDT of 100–400 days; VDT <100 days suggests infection or rapidly growing malignancy (SCLC, metastasis); VDT >400 days suggests benignity.
Subsolid nodule growth: Increase in size of the ground-glass component or new/increasing solid component is concerning for progression to invasive adenocarcinoma.
Stability: A solid nodule that remains unchanged in size on CT over ≥2 years is very likely benign (exception: pure GGN may require longer surveillance, up to 5 years).

Tissue Diagnosis

Obtaining an adequate tissue sample is a prerequisite for accurate histological classification, molecular testing, and treatment planning. The choice of biopsy technique depends on tumour location, size, proximity to airways, patient comorbidities, and local expertise. In Australia, access to advanced bronchoscopy techniques (EBUS, navigational bronchoscopy) has expanded significantly, with major tertiary centres offering these procedures routinely.

Bronchoscopy Techniques

Conventional Flexible Bronchoscopy

🔬

Conventional Bronchoscopy

White-light bronchoscopy with biopsy, brush, wash

Indication Central/endobronchial lesions; haemoptysis; staging airway assessment

Technique Flexible video bronchoscopy under moderate sedation (midazolam + fentanyl) or general anaesthesia

Sensitivity 70–90% for visible endobronchial lesions; 40–60% for peripheral lesions

Complications Pneumothorax <1%; haemorrhage 1–2%; hypoxia; arrhythmia

MBS item MBS 38500

Endobronchial Ultrasound–Guided Transbronchial Needle Aspiration (EBUS-TBNA)

🔬

EBUS-TBNA

Endobronchial ultrasound with transbronchial needle aspiration

Indication Mediastinal and hilar lymph node sampling; paratracheal/peribronchial lesions; mediastinal staging of NSCLC

Technique Dedicated linear-array EBUS bronchoscope under moderate sedation or GA; real-time ultrasound guidance with Doppler to identify vessels

Stations accessible 2R/L, 4R/L, 7, 10R/L, 11R/L (all standard mediastinal/hilar stations)

Sensitivity 89–93% (combined with EBUS-TBNA); NPV 91–95%

Specificity 99–100% (near-perfect)

Advantage over mediastinoscopy Less invasive; lower complication rate; repeatable; can be combined with EUS

Complications Pneumothorax <1%; bleeding <1%; infection rare

MBS item MBS 38556

✅

EBUS-TBNA is the first-line modality for mediastinal lymph node staging in NSCLC, as recommended by the British Thoracic Society (BTS), European Respiratory Society (ERS), and American College of Chest Physicians (ACCP). Surgical mediastinoscopy is reserved for cases where EBUS-TBNA is non-diagnostic or when station 5 and 6 (aortopulmonary window) nodes need sampling.

Navigational Bronchoscopy

🔬

Navigational / Robotic Bronchoscopy

Electromagnetic navigation bronchoscopy (ENB); robotic-assisted bronchoscopy

Indication Peripheral pulmonary nodules (typically 1–3 cm) inaccessible by conventional bronchoscopy

Techniques ENB (SuperDimension™ / Veran); shape-sensing robotic (Ion™); controller-based robotic (Monarch™)

Diagnostic yield 70–85% for lesions >1 cm; lower for lesions <1 cm; combined with radial EBUS improves yield to 85–90%

Advantage Lower pneumothorax rate (~2–4%) compared to CT-guided TTNB; allows biopsy + staging in single procedure

Availability in Australia Major tertiary centres (Royal Melbourne, Chris O'Brien Lifehouse, Royal Adelaide, Princess Alexandra, Fiona Stanley)

MBS status Not separately itemised — billed under bronchoscopy + imaging items

CT-Guided Transthoracic Needle Biopsy (TTNB)

🔬

CT-Guided Core Biopsy / FNA

Interventional radiology–performed percutaneous biopsy

Indication Peripheral lesions not amenable to bronchoscopic biopsy; pleural-based lesions; chest wall involvement

Needle type Core biopsy needle (18G coaxial) preferred over FNA for NSCLC — provides tissue architecture and adequate material for molecular testing

Sensitivity 90–95% for lesions >1 cm; 80–90% for lesions 0.5–1 cm

Complications Pneumothorax 15–25% (chest drain in 5–10%); haemoptysis 5–10%; haemothorax <1%; air embolism <0.1%

Contraindications Severe COPD (FEV1 <35%); bleeding diathesis (INR >1.5, platelets <50); contralateral pneumonectomy; pulmonary hypertension

MBS item MBS 55064

Surgical Biopsy

Video-assisted thoracoscopic surgery (VATS) wedge resection: Minimally invasive approach; gold standard for indeterminate nodules when less invasive methods are non-diagnostic; diagnostic accuracy ~100%.
VATS is preferred over open thoracotomy for diagnostic wedge resection due to reduced pain, shorter hospital stay, and lower morbidity.
Open thoracotomy: Reserved for cases where VATS is technically not feasible, or when diagnostic resection is combined with definitive lobectomy.
Mediastinoscopy: Historically the gold standard for mediastinal staging; now largely replaced by EBUS-TBNA; still indicated for station 5/6 sampling or EBUS non-diagnostic cases. MBS item 38504.

Molecular Testing (Comprehensive Genomic Profiling)

Molecular testing is mandatory for all newly diagnosed advanced NSCLC (stage IIIB–IV) and recommended for earlier stages where neoadjuvant/perioperative targeted therapy is being considered. Adequate tissue collection is critical — core biopsy specimens are strongly preferred over cytology alone.

🚨

Tissue is precious — biopsy once, test broadly. Request comprehensive molecular panel testing on initial biopsy to avoid repeat procedures. Insufficient tissue is the most common reason for delayed molecular results in Australia. For small biopsies or cytology specimens, reflex testing should be ordered at the time of pathology request.

Biomarker	Test Method	Prevalence in NSCLC	Approved Targeted Therapy (Australia)
EGFR mutations (ex19del, L858R, exon 20 ins, others)	PCR / NGS	15–20% (higher in never-smokers, Asian descent)	Osimertinib (Tagrisso®), erlotinib, gefitinib, afatinib, amivantamab, lazertinib
ALK rearrangement	FISH / IHC / NGS	3–5%	Alectinib (Alecensa®), lorlatinib, crizotinib, brigatinib, ceritinib
ROS1 rearrangement	FISH / NGS	1–2%	Crizotinib (Xalkori®), entrectinib (Rozlytrek®)
BRAF V600E	PCR / NGS / IHC	2–4%	Dabrafenib + trametinib (Tafinlar® + Mekinist®)
KRAS G12C	NGS	13%	Sotorasib (Lumakras®)
PD-L1 expression (TPS)	IHC (22C3, 28-8, SP263)	50–60% ≥1%; 20–30% ≥50%	Pembrolizumab, atezolizumab, nivolumab, durvalumab
NTRK fusions	NGS / FISH / IHC	<1%	Larotrectinib (Vitrakvi®), entrectinib (Rozlytrek®)
MET exon 14 skipping	NGS / RNA-based	3–4%	Capmatinib (Tabrecta®), tepotinib
RET fusions	NGS / FISH	1–2%	Selpercatinib (Retevmo®), pralsetinib (Gavreto®)
HER2 mutations	NGS	2–3%	Trastuzumab deruxtecan (Enhertu®)

Liquid Biopsy (Circulating Tumour DNA)

Role: When tissue biopsy is insufficient, technically not feasible, or as complement to tissue testing. Guardant360®, FoundationOne® Liquid CDx available in Australia through private pathology.
Sensitivity: 60–80% (lower than tissue for EGFR exon 20, ALK, and fusions); specificity >95%.
If liquid biopsy is negative: Tissue biopsy should still be pursued if clinically indicated (negative liquid biopsy does not exclude actionable mutations).
MBS status: Not currently funded under Medicare; out-of-pocket cost $2,000–5,000 through private pathology laboratories.

Staging & Treatment Planning

Accurate staging is the cornerstone of lung cancer management. The TNM 8th edition classification (IASLC, 2017) is the current standard, applied in both clinical (cTNM) and pathological (pTNM) forms. Staging determines operability, guides adjuvant therapy decisions, and identifies patients who may benefit from neoadjuvant or definitive chemoradiation approaches.

TNM 8th Edition — Key Changes and Definitions

T (Primary Tumour)

T Category	Size / Extent	Key Details
Tis	Carcinoma in situ	AIS or squamous carcinoma in situ
T1a(mi)	Minimally invasive adenocarcinoma	≤3 cm lepidic predominant, invasion ≤0.5 cm
T1a	≤1 cm
T1b	>1 cm, ≤2 cm
T1c	>2 cm, ≤3 cm
T2a	>3 cm, ≤4 cm	Or involves main bronchus (not carina); visceral pleura; atelectasis to hilum
T2b	>4 cm, ≤5 cm
T3	>5 cm, ≤7 cm	Or separate tumour nodule in same lobe; invasion of chest wall, pericardium, phrenic nerve
T4	>7 cm	Or invasion of mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, oesophagus, vertebral body, carina; separate nodule in different ipsilateral lobe

N (Regional Lymph Nodes)

N Category	Description	Stations Involved
N0	No regional lymph node metastasis	—
N1	Ipsilateral peribronchial/hilar nodes	Stations 10, 11, 12, 13
N2	Ipsilateral mediastinal/subcarinal nodes	Stations 2, 3, 4, 7, 8, 9
N3	Contralateral mediastinal/hilar; scalene/supraclavicular	Contralateral stations 2, 3, 4, 10; station 1

M (Distant Metastasis)

M Category	Description
M0	No distant metastasis
M1a	Contrateral lung nodules; pleural/pericardial nodules or effusion
M1b	Single extrathoracic metastasis in a single organ
M1c	Multiple extrathoracic metastases (one or multiple organs)

Stage Grouping (AJCC 8th Edition)

Stage I

T1–T2a, N0, M0

Tumour ≤4 cm, no nodal or distant disease. Curative surgery (lobectomy) is standard.

5-year survival: 68–92%

Stage II

T2b–T3, N0 or T1–T2, N1, M0

Larger tumour or ipsilateral hilar nodes. Surgery + adjuvant chemotherapy (cisplatin-based) ± immunotherapy.

5-year survival: 53–60%

Stage III

T3–T4 with N2, or T4 with N0–N1, M0

Locally advanced. Concurrent chemoradiation ± durvalumab consolidation (PACIFIC trial); selected N2 cases may undergo surgery after neoadjuvant therapy.

5-year survival: 13–36%

🚨

Stage IV (M1a–M1c): Metastatic disease. Systemic therapy is the mainstay — immunotherapy ± chemotherapy (PD-L1 ≥50%: pembrolizumab monotherapy or combination); targeted therapy if actionable driver mutation identified; palliative radiation for symptomatic metastases. Five-year survival approximately 5–10%, improving with immunotherapy and targeted agents.

Staging Investigations

ESSENTIAL CT chest/abdomen with IV contrast Assess primary tumour, mediastinal nodes, liver, adrenals. MBS item 56200/56204.

ESSENTIAL FDG PET-CT (whole body) Detect distant metastases; sensitivity 94%, specificity 87% for distant mets. MBS item 61338 (authority required).

ESSENTIAL Brain MRI (contrast-enhanced) Detect brain metastases (10–15% at diagnosis for NSCLC; 50–60% for SCLC). MBS item 63000/63003.

AVAILABLE Pulmonary function tests (spirometry + DLCO) Assess surgical fitness. Required before lobectomy/pneumonectomy. MBS item 11503.

AVAILABLE EBUS-TBNA / Mediastinoscopy Tissue confirmation of mediastinal nodes if PET-positive or clinical N2/N3 disease.

AVAILABLE Bone scan If PET-CT not available or equivocal for bone metastases. MBS item 61400.

AVAILABLE Endobronchial ultrasound (radial probe) For peripheral lesion characterisation and confirmation of tumour–vessel relationship preoperatively.

Mediastinal Staging Algorithm

Accurate mediastinal staging is critical because occult mediastinal nodal disease changes management from primary surgery to neoadjuvant therapy or definitive chemoradiation.

1

CT + PET-CT Assessment

If mediastinal nodes are normal on CT AND PET-negative (SUV <2.5) → proceed to surgery with intraoperative nodal sampling (low false-negative rate <10%).

2

EBUS-TBNA / EUS-FNA

If mediastinal nodes are PET-positive (SUV ≥2.5) or enlarged (>1 cm short axis) → tissue confirmation by EBUS-TBNA ± EUS-FNA is mandatory before excluding from surgery.

3

Repeat EBUS / Mediastinoscopy

If EBUS-TBNA is non-diagnostic but clinical suspicion remains high → repeat EBUS, combined EBUS/EUS, or surgical mediastinoscopy. Consider navigational biopsy if accessible.

4

MDT Decision

Integrate imaging, biopsy, molecular, and fitness data in MDT discussion to determine: upfront surgery, neoadjuvant therapy → surgery, or definitive chemoradiation.

Performance Status Assessment

Performance status (PS) is a critical determinant of treatment eligibility and prognosis. Australian lung cancer MDTs commonly use the ECOG (Eastern Cooperative Oncology Group) scale:

ECOG Grade	Description	Treatment Implications
0	Fully active; no restrictions	All treatment options (surgery, chemotherapy, immunotherapy, targeted therapy, chemoradiation)
1	Restricted in strenuous activity; ambulatory; light work possible	All treatment options with close monitoring
2	Ambulatory; capable of self-care; unable to work; up and about >50% of waking hours	May tolerate combination chemotherapy; immunotherapy; reduced-dose regimens. Surgery case-by-case.
3	Limited self-care; confined to bed/chair >50% of waking hours	Single-agent or immunotherapy preferred; best supportive care; palliative intent
4	Completely disabled; no self-care; confined to bed/chair	Best supportive care; palliative radiation if symptomatic
5	Dead	—

Multidisciplinary Team (MDT) Discussion

✅

MDT discussion is mandatory for every lung cancer diagnosis in Australia as per the Optimal Care Pathway for Lung Cancer (Cancer Council Victoria, endorsed by ACSQHC). The MDT should include: respiratory physician, thoracic surgeon, medical oncologist, radiation oncologist, radiologist (thoracic), pathologist, palliative care physician, lung cancer nurse coordinator, and allied health. Meetings should occur within 2 weeks of biopsy confirmation. All treatment decisions should be documented in the MDT outcome record and communicated to the patient's GP via the Optimal Care Pathway.

Key elements discussed at MDT:

Histological subtype and molecular results
Clinical and pathological TNM stage
Fitness for surgery (PFTs, cardiopulmonary exercise testing if borderline)
Fitness for systemic therapy (ECOG PS, comorbidities, geriatric assessment if ≥70 years)
Patient preferences and goals of care
Access to clinical trials
Palliative care integration (recommended from diagnosis for all patients, not just advanced disease)

Investigations Summary — Complete Workup Before Treatment

Investigation

Purpose

MBS Item

Notes

CT chest/abdomen + contrast

Local extent; nodes; liver; adrenals

56200/56204

Include adrenals; biphasic if renal mass

FDG PET-CT

Whole-body staging; distant mets

61338

Authority required; limited in brain

Brain MRI

Brain metastases

63000

Gadolinium-enhanced; essential for all NSCLC ≥ stage IB

Spirometry + DLCO

Surgical fitness

11503

Predicted postop FEV1 >40% predicted for lobectomy

EBUS-TBNA

Mediastinal nodal staging

38556

First-line for PET-positive mediastinal nodes

Molecular panel (NGS)

Targetable mutations; PD-L1

Hospital-funded

Mandatory for all NSCLC; request on initial biopsy

Routine bloods

FBC, LFTs, calcium, LDH, renal function

66500/66503

Hypercalcaemia in SCC; elevated LDH in SCLC

Special Populations

👴

Elderly Patients (≥70 years)

Screening and diagnosis

Upper age limit for screening is 80 years (USPSTF). Incidental nodule detection is more common due to higher CT utilisation. Comprehensive geriatric assessment (CGA) is recommended for patients ≥70 years before treatment decisions.

Surgical fitness

Physiological age rather than chronological age should guide surgical decisions. Frailty screening (Clinical Frailty Scale) and cardiopulmonary exercise testing (CPET) have higher discriminative value than age alone. VATS lobectomy is well tolerated in selected elderly patients.

Systemic therapy

Immunotherapy (pembrolizumab, atezolizumab) is better tolerated than combination chemotherapy in the elderly with ECOG PS 2. Single-agent chemotherapy (carboplatin) ± immunotherapy is preferred for PS 0–2. Avoid cisplatin if GFR <60 mL/min.

Biopsy considerations

Higher complication rates from CT-guided TTNB in elderly with COPD. Consider navigational bronchoscopy as a lower-risk alternative. EBUS-TBNA under moderate sedation is generally well tolerated.

🫘

Renal Impairment

Contrast-enhanced CT

eGFR <30 mL/min: use non-contrast CT or discuss with radiologist. IV contrast risk of contrast-induced AKI. Pre-hydration with 0.9% NaCl 1 mL/kg/hr for 6–12 hours if eGFR 30–45. Avoid metformin 48 hours post-contrast if eGFR <45.

PET-CT

No renal contraindication to FDG PET-CT (no iodinated contrast). Preferred staging modality in severe CKD.

Gadolinium MRI

Use group II gadolinium agents (gadobutrol, gadoterate) which have minimal nephrogenic systemic fibrosis risk. Avoid gadolinium in GFR <15 if possible.

👶

Young Adults (<40 years)

Epidemiology

Lung cancer in patients <40 years is rare (<2% of cases) but often diagnosed at advanced stage. Higher proportion of never-smokers and actionable driver mutations (EGFR 30–50%, ALK 15–25%, ROS1 higher prevalence).

Key consideration

Do not delay biopsy due to age — a lung mass in a young adult is cancer until proven otherwise. Comprehensive molecular testing is essential and may identify highly targetable mutations with excellent response rates.

🛡️

Immunocompromised Patients

Nodule evaluation

Fleischner Society guidelines do NOT apply. Infectious aetiology must be strongly considered (Nocardia, fungal infections, mycobacteria). PET-CT has lower specificity due to infectious/inflammatory FDG uptake. Biopsy is preferred over imaging surveillance.

Transplant recipients

Lung cancer risk is 2–4× higher in solid organ transplant recipients. Post-transplant lymphoproliferative disease (PTLD) may mimic lung cancer. Immunosuppression modification required if immunotherapy is considered — risk of allograft rejection.

🫁

Patients with Severe COPD / Pulmonary Fibrosis

Surgical fitness

Predicted postoperative (ppo) FEV1 and DLCO both >40% predicted to tolerate lobectomy. If ppo FEV1 or DLCO <30% → consider limited resection (segmentectomy/wedge), SBRT, or RFA. Cardiopulmonary exercise testing (CPET) with VO2 max is the gold standard for borderline cases. VO2 max <10 mL/kg/min = high surgical risk.

Screening

COPD and pulmonary fibrosis are independent risk factors for lung cancer. Consider annual LDCT in COPD patients with ≥20 pack-year history even if they don't meet strict USPSTF criteria (lower age threshold).

Idiopathic pulmonary fibrosis (IPF)

6–17× increased risk of lung cancer. Squamous cell carcinoma more common. Prognosis is poor. Surgical complications higher (acute exacerbation of IPF postoperatively). Anti-fibrotic therapy (nintedanib, pirfenidone) should be continued during cancer treatment.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health — Lung Cancer

Aboriginal and Torres Strait Islander Australians experience a disproportionate burden of lung cancer — the most commonly diagnosed cancer and leading cause of cancer death in Indigenous Australians. The age-standardised incidence rate is 1.8 times that of non-Indigenous Australians, and mortality rates are 1.9 times higher. Five-year survival is significantly lower (11% vs 19%), reflecting later-stage presentation, higher comorbidity burden, and reduced access to specialist services, particularly in remote communities.

Key Disparities

Smoking prevalence

Daily smoking among Aboriginal and Torres Strait Islander adults is approximately 37% (vs 10% non-Indigenous), contributing to the higher lung cancer incidence. Smoking during pregnancy remains a major concern with intergenerational health impacts.

Screening access

The proposed National Lung Cancer Screening Programme (LungCheck) must include culturally safe pathways for Aboriginal and Torres Strait Islander peoples, including community-controlled health services as entry points. Current LDCT screening is not widely accessible in rural and remote areas.

Diagnostic delay

Median time from symptom onset to diagnosis is longer in Indigenous Australians. Geographic remoteness, limited availability of bronchoscopy and PET-CT outside major cities, and cultural barriers to accessing tertiary hospitals contribute to delays.

Specialist access

EBUS-TBNA, navigational bronchoscopy, PET-CT, and comprehensive molecular testing are primarily available in metropolitan tertiary centres. Patients from remote communities may need to travel thousands of kilometres and be away from family and country for extended periods.

Treatment completion

Aboriginal and Torres Strait Islander patients are more likely to not receive active cancer treatment and more likely to discontinue treatment early. Cultural safety training for health professionals, Aboriginal health workers/ practitioners, and patient navigator programmes are essential.

Comorbidity burden

Higher prevalence of COPD, cardiovascular disease, diabetes, and chronic kidney disease affects treatment eligibility and tolerance. Comprehensive geriatric and comorbidity assessment with culturally appropriate support is critical.

Culturally Safe Practice Recommendations

Yarning-based communication: Use culturally appropriate communication approaches. Allow time for yarning and relationship building before discussing diagnosis. Understand that a cancer diagnosis carries significant cultural and spiritual weight in many Aboriginal and Torres Strait Islander communities.
Aboriginal and Torres Strait Islander health workers/practitioners: Involve Aboriginal health workers in screening, education, navigation, and follow-up. They provide cultural brokerage and build trust within communities.
Smoking cessation: Tackling smoking is the single most impactful intervention. The Tackling Indigenous Smoking programme provides community-based support. Pharmacotherapy (varenicline, NRT) should be offered with culturally appropriate counselling. Varenicline is PBS-listed as a general benefit.
Telehealth and outreach: Use telehealth for MDT discussions, pre-biopsy counselling, and follow-up. Outreach bronchoscopy and specialist clinics (e.g., through RHDAustralia, Cancer Council programmes) improve access in remote communities.
Family and community: Recognise the importance of family and community in decision-making. Treatment decisions may involve extended family and Elders. Ensure appropriate consent processes that respect collective decision-making preferences.
Palliative care: Culturally safe palliative care must be available, including support for dying on country where possible. Community-controlled palliative care services are limited but growing.
Data sovereignty: Engage with Aboriginal Community Controlled Health Organisations (ACCHOs) in programme design and evaluation. Respect data sovereignty principles in screening programme governance.

⚠️

Close the Gap Target 1: By 2031, reduce the rate of Aboriginal and Torres Strait Islander people dying from cancer by at least 15%. Achieving this for lung cancer requires addressing smoking prevalence, improving screening access, reducing diagnostic delays, and ensuring equitable access to molecular testing, targeted therapy, and immunotherapy.

📚 References

1. US Preventive Services Task Force. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(10):962–970. doi:10.1001/jama.2021.1117
2. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409. doi:10.1056/NEJMoa1102873
3. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382(6):503–513. doi:10.1056/NEJMoa1911793
4. MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology. 2017;284(1):228–243. doi:10.1148/radiol.2017161659
5. American College of Radiology. Lung-RADS Version 1.1: Lung CT Screening Reporting and Data System. Reston, VA: ACR; 2019.
6. Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest. 2017;151(1):193–203. doi:10.1016/j.chest.2016.10.010
7. Navani N, Nankivell M, Lawrence DR, et al. Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial. Lancet Respir Med. 2015;3(4):282–289. doi:10.1016/S2213-2600(15)00029-6
8. Cancer Council Victoria. Optimal Care Pathway for People with Lung Cancer. 2nd ed. Melbourne: Cancer Council Victoria; 2022.
9. Australian Institute of Health and Welfare. Cancer in Australia 2024. AIHW Cancer Series No. 142. Canberra: AIHW; 2024.
10. Conroy M, Pinsky PF. Indolent lung cancer—the overdiagnosis problem. JAMA Intern Med. 2023;183(3):283–284. doi:10.1001/jamainternmed.2022.6434
11. Ren S, Wang J, Ying J, et al. Consensus for molecular biomarker testing in non-small cell lung cancer. J Thorac Oncol. 2022;17(5):624–639. doi:10.1016/j.jtho.2021.12.013
12. Australian Government Department of Health and Aged Care. National Lung Cancer Screening Programme — Discussion Paper. Canberra: Commonwealth of Australia; 2023.
13. Lim E, Baldwin D, Beckles M, et al. Guidelines on the radical management of patients with lung cancer. Thorax. 2010;65(Suppl 3):iii1–iii27. doi:10.1136/thx.2010.145938
14. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409. doi:10.1056/NEJMoa1102873
15. Aiolfi A, Nosotti M, Bertoglio P, et al. Navigational bronchoscopy for peripheral pulmonary nodules: a systematic review and meta-analysis. Respiration. 2023;102(11):967–979. doi:10.1159/000534518